About Survodutide
Survodutide is studied as a dual GLP-1 receptor and glucagon receptor agonist in metabolic research. Supplied as a lyophilized powder for laboratory investigations into incretin/glucagon receptor pharmacology and energy-metabolism pathway markers in controlled experimental models. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Recent research on Survodutide: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Read Full Study on PubMedSurvodutide Once Weekly for the Treatment of Adults with Obesity.
Recent research on Survodutide: Survodutide Once Weekly for the Treatment of Adults with Obesity.
Read Full Study on PubMedAdditional Studies
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Recent research on Survodutide: Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Read on PubMedSurvodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
Recent research on Survodutide: Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
Read on PubMedBeyond weight loss: multisystem benefits of obesity medications.
Recent research on Survodutide: Beyond weight loss: multisystem benefits of obesity medications.
Read on PubMedEfficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Recent research on Survodutide: Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Read on PubMedMetabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.
Recent research on Survodutide: Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.
Read on PubMedA review of survodutide: a new dual acting agonist.
Recent research on Survodutide: A review of survodutide: a new dual acting agonist.
Read on PubMedRelated Research
Purchase Survodutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.